I have been involved in the Kidney Transplant Program as its Medical Director at RIH since its inception in 1996. During that time, I have been involved in the care of approximately 600 new transplant patients. I have also been involved in the training of over 25 renal fellows as well as providing education to both the medical and surgical housestaff. I have co-authored over 40 peer-reviewed scientific papers. My primary research interests include different aspects of clinical transplantation. These include pharmacokinetic studies of various immunosuppressive medications and how these may effect different transplant populations. I have also pursued studies that helped to identify and treat patients at increased risk for recurrent primary renal disease in the post-transplant setting.
Mendonza AE, Gohh RY, Akhlaghi F. Analysis of Mycophenolic acid in saliva using liquid chromatography tandem mass spectrometry. Ther Drug Monit 2006; 28: 402-406.
Grossberg JA, Reinert SE, Monaco AP, Gohh R, Morrissey PE. Utility of a mathematical nomogram to predict delayed graft function: a single center experience. Transplantation. 2006 Jan 27;81(2):155-9.
Akhlaghi F, Patel CG, Zuniga XP, Halilovic J, Preis IS, Gohh RY. Pharmacokinetics of Mycophenolic Acid and Metabolites in Diabetic Kidney Transplant Recipients. Ther Drug Monit. 2006 Feb;28(1):95-101.
Yango AF, Gohh RY, Monaco AP, Reinert SE, Gautam A, Dworkin LD, Morrissey PE. Excess risk of renal allograft loss and early mortality among elderly recipients is associated with poor exercise capacity. Clin Nephrol 2006 Jun; 65 (6); 401-7..
Gautam A, Morrissey PE, Brem AS, Fischer SA, Gohh RY, Yango AF, Monaco AP. Use of an immune function assay to monitor immunosuppression for treatment of post-transplant lymphoproliferative disorder. Pediatr Transplant. 2006 Aug;10(5):613-6.
Gautam A, Morrissey PE, Gohh R, Yango A, Monaco AP. Experience with sirolimus for calcineurin minimization/elimination in pancreas-after-kidney transplantation. Transplant Proc. 2005 Oct;37(8):3542-3
Gohh RY, Yango AF, Morrisey PE, Monaco AP, Gautam AG, Sharma M, McCarthy ET, Savin, VJ. Preemptive plasmapheresis and recurrence of FSGS in high-risk renal transplant recipients. Am J Transplant 2005 Dec; 5(12): 2907-2912.
Morrissey PE, Reinert S, Gohh R, Yango A, Gautam A, Monaco AP. Factors contributing to acute rejection in renal transplantatation: the role of noncompliance. Transplant Proc 2005 Jun;37(5):2044-7.
Morrissey PE, Dube C, Gohh R, Yango A, Gautam A, Monaco AP. Good samaritan kidney donation. Transplantation. 2005 Nov 27;80(10):1369-73.
Morrissey PE, Gohh R, Yango A, Gautam A, Monaco AP. Renal transplant survival from older donors: a single center experience.Arch Surg. 2004 Apr;139(4):384-9.
Mendonza A, Akhlaghi F, Gohh R. Determination of cyclosporine in saliva using liquid chromatography-tandem mass spectometry. Ther Drug Monit. 2004 Oct;26(5):569-575.
Urbina BY, Gohh R, Fischer SA. Oerskovia xanthineolytica endocarditis in a renal transplant patient: case report and review of the literature. Transplant Infect Dis 2003; 5: 195-198.
Yango A, Morrissey P, Zanabli A, Beaulieu J, Shemin D, Dworkin L, Monaco A, Gohh R. Comparative study of prophylactic oral ganciclovir and valacyclovir in high-risk kidney transplant recipients. Nephrol Dial Transplant 2003 Apr; 18(4): 809-13.
Yango A, Morrissey P, Gohh R, Wahbeh A, Monaco A. Donor-transmitted parvovirus infection in a kidney transplant recipient presenting as pancytopenia and allograft dysfunction. Transpl Infect Dis 2002; 4(3): 163-166.
Morrissey PE, Ramirez PJ, Gohh RY, Yango AF, Kestin A, Madras PN, Monaco AP. Management of thrombophilia in renal transplant patients. Am J Transplant 2002; 2(9): 872-876.
Yango A, Morrissey P, Monaco A, Butera B, Gohh RY. Successful treatment of tacrolimus-associated thrombotic microangiopathy with sirolimus conversion and plasma exchange. Clin Nephrol 2002; 58(1): 77-78.
Ramirez P, Gohh R, Kestin A, Monaco A, Morrissey P. Renal allograft loss due to proximal extension of ileofemoral deep venous thrombosis. Clin Transplant 2002; 16(4): 310-313.
Morrissey P, Gohh R, Monaco A. A novel scale of immunosuppression exposure and correlation to outcomes after renal transplantation. Transplant Proc 2002; 34(5): 1640.
Yango A, Morrissey P, Monaco A, Gohh R, Centracchio J, Dworkin L. Renal production of hepatocyte growth factor increases after unilateral nephrectomy in man. Transplant Proc 2002; 34(8): 3128-9.
Bostom AG, Kronenberg F, Gohh RY, Schwenger V, Ritz E, Selhub J. Chronic renal transplantation: a model for hyperhomocysteinemia in renal insufficiency. Atherosclerosis 2001; 156(1): 227-230.
Gohh RY, Morrissey PE, Madras PN, Monaco AP. Controversies in organ donation: The altruistic living donor. Nephrol Dial Transplant 2001; 16(3): 619-621.
Beaulieu AJ, Gohh RY, Han HW, Hakas D, Jacques PF, Selhub J, Bostom AG. Enhanced reduction of fasting total homocysteine levels with supraphysiological versus standard multivitamin dose folic acid supplementation in renal transplant recipients. Arterioscl Thromb Vasc Bio 2000; 19(12): 2918-2921.
Bostom AG, Shemin D, Gohh RY, Beaulieu AJ, Jacques PF, Dworkin L, Selhub, J. Treatment of mild hyperhomocysteinemia in renal transplant recipients versus hemodialysis patients. Transplantation 2000; 69(10): 2128-2131.
Bostom AG, Gohh RY, Beaulieu AJ, Han H, Jacques PF, Selhub J, Dworkin L, Rosenberg IH. Determinants of fasting plasma total homocysteine levels among stable renal transplant recipients in the era of folic acid fortified cereal grain flour. Transplantation 1999; 68: 257-261.
Bostom AG, Gohh RY, Liagaudas G, Beaulieu AJ, Han H, Jacques PF, Dworkin L, Rosenberg IH, Selhub J. Prevalence of mild fasting hyperhomocysteinemia in renal transplant versus coronary artery disease after fortification of cereal grain flour with folic acid. Atherosclerosis 1999; 145: 221-224.
Bostom AG, Gohh RY, Bausserman L, Hakas D, Jacques PF, Selhub J, Dworkin L, Rosenberg IH. Serum cystatin C as a determinant of fasting total homocysteine levels in renal transplant recipients with a normal serum creatinine. J Am Soc Nephrol 1999; 10: 164-166.
Morrissey P, Gohh R, Madras P, Monaco AP. Pulmonary fibrosis secondary to administration of mycophenolate mofetil [letter]. Transplantation 1998; 1414.
Morrissey PE, Gohh RY, Madras PN, Shaffer D, Davis C, Conway P, Sahyoun A, Monaco AP. Etiology of early renal allograft dysfunction after live donor renal transplantation. Translant Proc 1998; 30.
Bostom AG, Shemin DG, Gohh RY, Tsai MY, Hopkins-Garcia BJ, Nadeau MS, Bianchi L, Jacques PF, Rosenberg IH, Selhub J. Lower fasting total plasma homocysteine levels in stable renal transplant recipients versus maintenance hemodialysis patients. Transplant Proc 1998; 30: 160-162.
Bostom AG, Gohh RY, Beaulieu A, Nadeau MR, Hume AL, Jacques PF, Selhub J, Rosenberg IH. Brief Communication: Treatment of hyperhomocysteinemia in renal transplant recipients: a randomized, placebo-controlled trial. Ann Int Med 1997; 127: 1089-1092.
Bostom AG, Gohh RY, Tsai MY, Hopkins-Garcia BJ, Nadeau MS, Bianchi L, Jacques PF, Rosenberg IH, Selhub J. Excess prevalence of fasting and post-methionine loading hyperhomocysteneimia in stable renal transplant recipients. Aterioscl Thromb Vasc Biol 1997; 1.
Gohh RY, Williams ME, Crosson AW, Federman M, Zambetti FX. Late renal allograft failure secondary to thrombotic microangiopathy associated with disseminated malignancy. Am J Nephrol 1997; 17: 176-180.
Morrissey PE, Gohh R, Shaffer D, Crosson A, Madras PN, Sayhoun AI, Monaco AP. Correlation of clinical outcomes after tacrolimus conversion for resistant kidney rejection or CyA toxicity with pathologic staging by the Banff criteria. Transplantation 1997; 63: 845-848.
Hsieh F, Gohh RY, Dworkin LD. Acute renal failure and the MELAS syndrome, a mitochondrial encephalomyopathy. J Am Soc Nephrol 1996; 7: 647-652.
I am interested in learning why some immunosuppressive drugs are more effective in preventing rejection in certain patient populations compared to others, with a specific interest in the diabetic population. I am also involved in studies which look at the most effective immunosuppressive drug combinations in preventing rejection and long-term outcomes. Other studies focus on the the effect of kidney transplantion on the quality of life of these unfortunate patients.
I have involved in a number of industry-sponsored, multi-centered studies looking at the effectiveness of different immunosuppressive drug regimens in not only preventing allograft rejection, but also long-term outcomes. More recently, I have focused my attention on the pharmacokinetic and pharmacodynamic properties of different immunosuppressive agents in different study populations. I am particularly interested in learning more about the diabetic population, since these individuals are more prone to complications post-transplantation. In addition, I am currently performing a study looking at howcorrecting uremic physiology affects quality-of-life paramaters such as exercise tolerance.
"Folic acid treatment to reduce fasting plasma total homocysteine levels in renal transplant recipients: a dose-finding study." Principal Investigator. Study sponsored by the National Kidney Foundation, 1998-1999, $15,000, 7/98-6/99.
"Subclinical carotid arteriosclerosis in renal transplant recipients: association with aerobic capacity and traditional cardiovascular disease risk factors." Principal Investigator. Study sponsored by Lifespan Developmental Grant, $17,146.25, 3/98-2/99.
"A multicenter, randomized, open label trial of Simulect with rapid steroid withdrawal vs. Simulect with standard treatment in subjects treated with Neoralâ and Cellceptâ for the prevention of acute rejection in renal transplantation." Principal Investigator. Study sponsored by Novartis Pharmaceuticals. Study No: CHI INT 12, $21,560. 5/98-3/02.
"A phase IV epidemiologic demonstration of SangCyAÔ (Cyclosporine Oral Solution, USP [Modified]) safety using a pharmacovigilence data collection system." Principal Investigator. Study sponsored by Sangstat Pharmaceutical Corporation, $5,000, 10/99-5/00.
"An open-label, multicenter study to further characterize the clinical utility and safety of Rapamuneâ and Cyclosporine combination treatment in de novo renal allograft recipients." Principal Investigator. Study sponsored by Wyeth-Ayerst Laboratories, $37,500, 11/99-3/02.
"A comparative, open-label study to evaluate graft function in de novo renal allograft recipients treated with either a 'reduced dose' or a 'standard dose' of Cyclosporine in combination with Rapamuneâ (Sirolimus) + Corticosteroids." Principal Investigator. Study sponsored by Wyeth-Ayerst Pharmaceuticals, $81,400, 5/00-present.
"A randomized, open-label preference study of Gengraf compared to Neoral in stable solid-organ transplant subjects." Principal Investigator. Study sponsored by Abbott Pharmaceuticals, $12,500, 6/00-3/02.
"Pilot study to induce specific unresponsiveness with donor specific peripheral blood mobilized bone marrow stem cells (PBSCs) in recipients of living donor, mismatched renal allografts treated with Thymoglobulin and standard cyclosporine based immunosuppression." Co-Principal Investigator. Study sponsored by AMGEN Pharmaceutical Corporation, $22,500, 8/00-present.
"Rapamune Outcomes Assessment Registry." Principal Investigator. Study sponsored by Wyeth-Ayerst Pharmaceuticals, $12,000, 10/00-present.
"Simulect induction followed by overall reduction in immunosuppression exposure after renal transplantation (SIRE)." Co-investigator. Study sponsored by Novartis Pharmaceuticals, 2001-present.
"Registry of Simulect use in living donor renal transplantation (ReSULTS)." Co-investigator. Study sponsored by Novartis Pharmaceuticals, 2001-present.
"A 1-year multicenter, randomized study of safety and tolerability and efficacy of two doses of Certican (RAD001) with steroids and optimized administration of Neoral in de novo renal transplant recipients." Co-investigator. Study sponsored by Novartis Pharmaceuticals, 2002-present.
"A prospective, randomized, multicenter double blind study of early corticosteroid withdrawal cessation vs. long-term maintenance corticosteroid therapy with Prograf and Cellcept in primary renal transplant recipients." Co-investigator. Study sponsored by Fujisawa Pharmaceuticals, $15,000, 2002-present.
"A multicenter study evaluating once every other week subcutaneous administration of Aranesp (darbepoetin alfa) in subjects with anemia of chronic renal insufficiency." Co-investigator. Study sponsored by Amgen Pharmaceuticals, $6200, 8/02-present.
"An open-label, concentration-controlled, randomized, 12 month study of Prograf + Rapamune + Corticosteoids compared to Cyclosporine capsules, USP (modified) + Ramapune + Corticosteroids in high-risk renal allograft recipients." Principal Investigator. Study sponsored by Wyeth-Ayerst Pharmaceuticals, $115,900, 9/03-present.
"Evaluation of immune globulin, intravenous, human manufactured using a new chromatographic method (IgIV-C), as an agent to reduce anti-HLA antibodies and improve transplantation results in cross match positive living donor kidney allograft recipients (Protocol IgO3)." Principal Investigator. Study sponsored by the NIH, $18,746, 6/03-3/05.
"Pharmacokinetics of mycophenolic acid in diabetes (Protocol CEL386)." Principal Investigator. Study sponsored by Roche Pharmaceuticals, $25,721, 6/03-7/04..
"A one-year, multicenter, double-blinded, double-dummy, randomized study to evaluate the safety and efficacy of two doses of FTY720 combined with full-dose Neoral® and steroids versus Cellcept® combined with full-dose Neoral® and steroids in de novo renal transplant recipients. Study sponsored by Novartis Pharmaceuticals, 2004- 09/05.
"Diabetic incidence after renal transplantation: Neoral C-2 monitoring vs. TacrolimusA 6-month open-label multicenter, randomized control study to compare the incidence of new onset diabetes mellitus and glucose metabolism in patients receiving Neoral with C-2 monitoring vs. tacrolimus after de novo kidney transplantation." Study sponsored by Novartis Pharmaceuticals, $124,728, 9/04-present.
"A randomized, open-label study to compare the safety and efficacy of two different Rapamune regimens with a Tacrolimus and Mycophenolate Mofetil regimen in de novo renal allograft recipients." Study sponsored by Wyeth-Ayerst Pharmaceuticals, $115,618, 8/04- present.
"An open-label, prospective, randomized, controlled, multi-center study assessing fixed dose vs. concentration-controlled Cellcept regimens for patients following single organ renal transplantation in combination with full dose and reduced dose calcineurin inhibitors." Study sponsored by Roche Laboratories, $202,375, 10/04- present.
"Pharmacokinetics and Dynamics of Mycophenolate Sodium in Diabetes." Study sponsored by Novartis Pharmaceuticals Corporation, $23,526, 5/05- 3/06.
Alpha Omega Alpha, 1990
Meharry Medical College
Young Investigator's Award
American Society of Transplant Physicians
Dean's Teaching Excellence Award, 2003, 2004
Brown University School of Medicine
ESRD Network of New England
Board of Directors and Chairman of Transplant Committee,
Coalition of Donation/RI Organ Donor Awareness Committee
Board of Directors, 1997-2000, 2006-
American Society of Internal Medicine/ American College of Physicians
Rhode Island Chapter Council, 1997-2000
American Society of Nephrology, 1988-
National Kidney Foundation
Regional Board of Directors of MA and RI, 1998-2003
Medical Advisory Board, 1998-2000
International Society of Nephrology, 1999-
American Diabetic Association, 1999-
American Society of Transplanation, 2001-
I am actively involved in the education and research activities of the fellows of the Division of Renal Diseases at Brown University. These include formal didactic lectures and serving as the attending physician in both the Renal Consult and Transplant Services. I have also served as the longitudingal clinic preceptor for numerous medical residents and students I am also involved in the education of both the the medical and surgical residents. I serve as the attending physician of the Med A renal service. I also frequently provide lectures on renal pathophysiology to the medical housestaff and medical students. In the past, I have also lectured and served as small group facilitator of Renal Pathophysiology (Biomed 281).